The future of vitamin D analogs
- Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
The active form of vitamin D3, 1,25-dihydroxyvitamin D3, is a major regulator of bone and calcium homeostasis. In addition, this hormone also inhibits the proliferation and stimulates the differentiation of normal as well as malignant cells. Supraphysiological doses of 1,25-dihydroxyvitamin D3 are required to reduce cancer cell proliferation. However, these doses will lead in vivo to calcemic side effects such as hypercalcemia and hypercalciuria. During the last 25 years, many structural analogs of 1,25-dihydroxyvitamin D3 have been synthesized by the introduction of chemical modifications in the A-ring, central CD-ring region or side chain of 1,25-dihydroxyvitamin D3 in the hope to find molecules with a clear dissociation between the beneficial antiproliferative effects and adverse calcemic side effects. One example of such an analog with a good dissociation ratio is calcipotriol (Daivonex®), which is clinically used to treat the hyperproliferative skin disease psoriasis. Other vitamin D analogs were clinically approved for the treatment of osteoporosis or secondary hyperparathyroidism. No vitamin D analog is currently used in the clinic for the treatment of cancer although several analogs have been shown to be potent drugs in animal models of cancer. Transcriptomics studies as well as in vitro cell biological experiments unraveled basic mechanisms involved in the antineoplastic effects of vitamin D and its analogs. 1,25-dihydroxyvitamin D3 and analogs act in a cell type- and tissue-specific manner. Moreover, a blockade in the transition of the G0/1 toward S phase of the cell cycle, induction of apoptosis, inhibition of migration and invasion of tumor cells together with effects on angiogenesis and inflammation have been implicated in the pleiotropic effects of 1,25-dihydroxyvitamin D3 and its analogs. In this review we will give an overview of the action of vitamin D analogs in tumor cells and look forward how these compounds could be introduced in the clinical practice.
The active form of vitamin D3, 1,25-dihydroxyvitamin D3 [1α,25(OH)2D3; 1] (Table 1), is mostly known for its effects on bone, calcium, and phosphate homeostasis. Next to these classical effects, 1,25(OH)2D3 also exerts so-called non-classical effects on various tissues which express the vitamin D receptor (VDR) as well as the enzymes that are responsible for activating the hydroxylations of vitamin D3, which is essential for the formation of 1,25(OH)2D3. Thus, most tissues have the ability to convert vitamin D3 into its active form, 1,25(OH)2D3, which in turn will bind the VDR in order to positively or negatively influence target genes via binding of the 1,25(OH)2D3/VDR complex to vitamin D receptor elements (VDRE). Non-classical properties of 1,25(OH)2D3 include prodifferentiating and antiproliferative effects on normal and cancer cells (Colston et al., 1981; Jensen et al., 2001) as well as immunomodulatory effects. However, in order to obtain these non-classical effects, 1,25(OH)2D3 doses of the nanomolar range are necessary, while physiological 1,25(OH)2D3 serum concentrations are in the picomolar range. Since supraphysiological doses of 1,25(OH)2D3 result in hypercalcemia, 1,25(OH)2D3 analogs were developed to minimize the calcemic side effects while preserving or augmenting the beneficial effects of 1,25(OH)2D3. Both industry and academic institutions have synthesized a vast amount of vitamin D analogs. Some of these analogs have tissue-specific effects with low calcemic side effects and can be given at higher doses compared to the mother compound.
Clinically Approved Vitamin D Analogs
Given the huge amount of vitamin D analogs that have been synthesized during the years, it is nearly impossible to give an overview of them all. In the first part we will discuss vitamin D analogs that are clinically approved (Table 2). For several conditions such as secondary hyperparathyroidism, psoriasis and osteoporosis, vitamin D analogs are frequently used as a treatment option. Paricalcitol  and doxercalciferol  are vitamin D2 analogs approved for therapeutic use of secondary hyperparathyroidism. In Japan falecalcitriol  and maxacalcitol  are also used to treat this disease. Secondary hyperparathyroidism is characterized by elevated parathyroid hormone (PTH) levels in response to hypocalcemia and is often caused by chronic kidney disease. Above-mentioned vitamin D analogs suppress PTH, as does 1,25(OH)2D3, but without inducing severe hypercalcemia. Clinical studies with chronic kidney disease patients show that different analogs induce a stronger PTH suppression compared to placebo treatment (Hamdy et al., 1995; Coburn et al., 2004; Coyne et al., 2006). Also, end-stage renal disease patients treated with these analogs often have a better survival (Teng et al., 2003; Tentori et al., 2006; Shinaberger et al., 2008). However, few studies with chronic kidney disease and end-stage renal disease patients directly compare the effects of 1,25(OH)2D3 with its analogs.
Psoriasis, a hyperproliferative condition of the skin, is also treated with vitamin D analogs. Tacalcitol , calcipotriol  and the recently approved maxacalcitol  are used either as monotherapy or in combination with topical steroids such as betamethasone dipropionate to treat psoriasis. The analogs exert prodifferentiating and antiproliferative effects on keratinocytes and also possess important anti-inflammatory properties. Furthermore, alfacalcidol ([1α(OH)D3; 8], actually a pre-metabolite of 1,25(OH)2D3) and eldecalcitol (ED-71)  are used in Japan in the treatment of osteoporosis. The recently approved eldecalcitol  is more effective than 1,25(OH)2D3 and alfacalcidol  in increasing bone mineral density and mechanical strength in ovariectomized rats (Uchiyama et al., 2002). Various studies in mouse models as well as in patients show that treatment with eldecalcitol  leads to higher lumbar and hip bone mineral density and a lower incidence of new vertebral fractures (Ito et al., 2011; Matsumoto et al., 2011; Harada et al., 2012; Hagino et al., 2013), making eldecalcitol  a very promising new analog for the treatment of osteoporosis.
Genome- and Transcriptome-Wide Effects of Vitamin D Analogs
The exact mechanism of action of vitamin D analogs still has to be deciphered. The reason why specific analogs have superagonistic actions on specific tissues remains unknown, however several studies have tried to elucidate the mechanisms behind these tissue-specific effects. The catabolism of vitamin D analogs is one of the mechanisms that have an effect on their potency. Modifications of the side chain of 1,25(OH)2D3 are known to slow down its catabolism by CYP24A1 (Jones, 1997). Seocalcitol (EB1089)  and 20-epi-1,25(OH)2D3  are degraded slower compared to 1,25(OH)2D3 leading to a longer exposure of these analogs to the tissues (Hansen and Maenpaa, 1997; Kissmeyer et al., 1997; Shankar et al., 1997; Zella et al., 2009). The metabolites formed after catabolism of lexicalcitol  are more active than the ones formed after 1,25(OH)2D3 is catabolized (Dilworth et al., 1997) and this analog is also more effective in slowing down the degradation rate of the VDR (van den Bemd et al., 1996). Moreover, since some cell types prefer specific catabolism pathways and enzymes above others, the degradation process may also contribute to the tissue-specific activity of vitamin D analogs. The affinity for the vitamin D binding protein (DBP) also plays a role in the activity of vitamin D analogs. Maxacalcitol  for example has a 500 times lower affinity for DBP and is thus cleared faster from the circulation than 1,25(OH)2D3 (Okano et al., 1989a). This analog has a short effect on bone and intestine, tissues responsible for calcium homeostasis, and a longer effect on PTH levels, making this analog ideal for the treatment of secondary hyperparathyroidism. However, it is still unknown why the duration of the effects is different in these tissues. Eldecalcitol  on the other hand has a higher DBP affinity compared to the mother compound, leading to longer sustained plasma levels and is thus more suitable for the treatment of osteoporosis (Okano et al., 1989b).
Another mechanism that contributes to the superagonistic effects of vitamin D analogs is their interaction with the VDR, co-activators and VDREs. 20-epi-1,25(OH)2D3, a C-20 epimer of 1,25(OH)2D3 , promotes heterodimerization between VDR and retinoid X receptor (RXR) (Liu et al., 2001). 20-epi-1,25(OH)2D3  and other analogs like maxacalcitol , CD578 , inecalcitol , and TX527  require lower concentrations to recruit specific coactivators to the VDR/RXR/VDRE complex (Liu et al., 2000; Eelen et al., 2005, 2008; Schwinn and DeLuca, 2007). Approximately 10- fold lower doses of inecalcitol  and TX527  are needed, compared to 1,25(OH)2D3, to acquire the same amount of co-activator interactions (Eelen et al., 2005). Vitamin D analogs might also be able to induce tissue-specific effects by favoring binding to specific VDRE motifs in target gene promoters. Analogs with a 20-methyl group as well as seocalcitol  bound to a VDR/RXR complex preferably interact with the IP9 type of VDRE (Danielsson et al., 1996; Quack and Carlberg, 1999).
On the genome level, studies using chromatin immunoprecipitation (ChIP) and micro-array techniques have investigated 1,25(OH)2D3-regulated genes in different cell lines. One ChIP study compared the binding sites of the VDR in intestinal tissue after 1,25(OH)2D3 or 20-epi-1,25(OH)2D3  treatment. This study shows that both 1,25(OH)2D3 and 20-epi-1,25(OH)2D3  induce VDR binding to CYP24A1 and TRPV6 loci in the intestine, but the analog elicits a prolonged VDR binding to these genes leading to its superagonistic characteristics such as hypercalcemia in vivo (Zella et al., 2009). Other ChIP studies have tried to investigate the molecular mechanisms of some analogs in different tissues. In osteoblast cell models 2MD  bound to the VDR is able to bind VDREs at lower concentrations compared to 1,25(OH)2D3 (Yamamoto et al., 2003). Seocalcitol , on the other hand, mediates the dissociation of Williams syndrome transcription factor of the aromatase promoter leading to inhibition of aromatase expression and activity in breast cancer cells which is one of the main therapeutic strategies in breast cancer patients (Lundqvist et al., 2013). In a recent paper binding sites of VDR and mothers against decapentaplegic homolog 3 (SMAD3) were investigated in hepatic stellar cells. These transforming growth factor β1 (TGFβ1)-activated cells play an important role in liver fibrosis. In this study it is shown that VDR and SMAD3 can at least transiently co-occupy the same genomic sites and function as enhancers of pro-fibrotic gene expression. However, when calcipotriol  is added, the TGFβ1-induced recruitment of SMAD3 is compromised and binding of VDR to these genomic sites is enhanced 10-fold meaning that liganded VDR antagonizes SMAD residency on chromatin and thereby suppresses pro-fibrotic gene expression (Ding et al., 2013). This genomic feedback circuit is a previously unknown mechanism of calcipotriol .
Micro-array studies in various cancer cell lines such as leukemia, prostate, breast, colorectal, and ovarian cancer show that a variety of gene clusters are influenced by 1,25(OH)2D3 and its analogs (reviewed in Kriebitzsch et al., 2009). Cell growth, apoptosis, cellular adhesion and extracellular matrix composition, oxidative stress, immune function, intra- and intercellular signaling and steroid/lipid metabolism are frequently modulated processes in cells by 1,25(OH)2D3 and its analogs. However, when different cell lines are compared, few 1,25(OH)2D3/analog-regulated genes overlap, which suggests that 1,25(OH)2D3 and its analogs behave in a cell type- and tissue-specific way. Also studies using human T-cells (Baeke et al., 2011), rat ventricular heart tissue (Bae et al., 2011), and bone marrow-derived mouse dendritic cells (Griffin et al., 2004) have researched the impact of 1,25(OH)2D3 analogs on gene expression. In these studies genes important for cell growth, cell death and cell signaling are regulated, but also a large set of genes implicated in the migration of T-cells and dendritic cells are influenced. TX527  imprints human T-cells with a migratory signature and targets them to sites of inflammation (Baeke et al., 2011). Paricalcitol  treatment of rats with cardiac hypertrophy prevents the progression of cardiac hypertrophy and the development into chronic heart failure. The genomic changes associated with cardiac hypertrophy in the ventricular heart tissue of these rats are, in part, reversed by paricalcitol  administration (Bae et al., 2011). Furthermore, other studies investigated if 1,25(OH)2D3 analogs are able to bind and regulate different genes compared to 1,25(OH)2D3. All conducted studies conclude that 1,25(OH)2D3 and its analogs induce or repress the same set of genes. Seocalcitol  induces a less malignant phenotype in SCC25 squamous cell carcinoma cells and modulates expression of genes important in cell cycle progression, cell adhesion, extracellular matrix composition, intra- and intercellular signaling, G-protein coupled function, redox balance, and steroid metabolism. In these cells, seocalcitol  regulates the same genes compared to 1,25(OH)2D3, however gene regulation by 1,25(OH)2D3 is more transient (Lin et al., 2002). Also WY1112, a seco-9,11-bisnor-17-methyl analog lacking the C-ring and with a 21-epi side chain which is fluorinated on C26 and C27 , was investigated in MCF-7 breast cancer cells. Despite the 400-fold stronger antiproliferative capacity of WY1112 , the same genes are upregulated after 1,25(OH)2D3 or WY1112  treatment. However, the induction ability is much higher for the analog (Vanoirbeek et al., 2009). When treating human coronary artery smooth muscle cells with equal amounts of 1,25(OH)2D3 or paricalcitol  the same genes are regulated (Wu-Wong et al., 2007; Shalhoub et al., 2010). In conclusion, differences in action and capacity of vitamin D analogs are more due to their specific sensitivities to metabolism and their specific interaction with the VDR, co-activators and VDREs than from different gene regulations. However, to our knowledge no studies have yet looked into the potential differences elicited by analogs compared to 1,25(OH)2D3 in the fields of proteomics and epigenetics, which could help to understand the molecular mechanism of 1,25(OH)2D3 and its analogs on different cell and tissue types.
Effects of Vitamin D Analogs in Cancer
The use of 1,25(OH)2D3 for the treatment of cancer gained interest since many tissues express vitamin D metabolizing enzymes as well as the VDR and because 1,25(OH)2D3 has potent antiproliferative and prodifferentiating effects on normal and malignant cell lines. Several analogs evaluated in vitro show stronger antiproliferative and prodifferentiating effects compared to the mother compound in different cancer cell lines. These compounds are further evaluated in rodent models to assess their anti-cancer activity and safety in vivo. All in vivo studies using rodent cancer models that were published between 2007 and 2013 are summarized in Table 3. For studies preceding 2007, the reader is referred to other reviews (Eelen et al., 2007). In most studies the growth of the tumor is inhibited without inducing severe hypercalcemia when appropriate doses of vitamin D analogs are used (Abe et al., 1991; Kawa et al., 1996, 2005; Akhter et al., 1997, Blutt et al., 2000; Prudencio et al., 2001; Grostern et al., 2002; Flanagan et al., 2003; Albert et al., 2004a; Wietrzyk et al., 2004; Zhang et al., 2005; Fichera et al., 2007; van Ginkel et al., 2007; Ghous et al., 2008; Lee et al., 2008; Schwartz et al., 2008; Gonzalez-Pardo et al., 2010; Seubwai et al., 2010; Berkovich et al., 2013; Chiang et al., 2013). However, in some models the analog dose that is effective in inhibiting tumor growth also causes hypercalcemia and lower survival of the treated animals (Albert et al., 2004b). Not only tumor proliferation is modulated by vitamin D analogs, also apoptosis, angiogenesis, migration of tumor cells, etc. are affected by some analogs. In xenograft studies where apoptosis in the tumor was investigated after vitamin D analog treatment, apoptosis or the necrotic field in the tumor is augmented (James et al., 1998; VanWeelden et al., 1998; Hara et al., 2001; Vegesna et al., 2003; Lambert et al., 2010; Park et al., 2012). Inecalcitol (Hybrigenics, France)  treatment of mice with squamous cell carcinoma xenografts increases apoptosis in the tumors and this increase is higher for the analog compared to 1,25(OH)2D3, while the capacity of the analog to inhibit proliferation is equal compared to the mother compound (Ma et al., 2013). Most studies agree that vitamin D analogs also have an effect on tumor metastasis. Seocalcitol  reverses the growth-stimulatory effects of parathyroid hormone-related protein (PTHrP), which plays a major role in prostate cancer progression and metastasis, in a xenograft mouse model of prostate cancer. The same study shows that seocalcitol  also inhibits migration and invasion of these prostate cancer cells in vitro (Bhatia et al., 2009). This analog also reduces the number and surface area of bone metastasis originating from intracardially injected breast cancer cells (El Abdaimi et al., 2000). Vitamin D analogs are thus able to reduce the number and growth of metastasis originating from various types of cancer cells (Sato et al., 1984; Lokeshwar et al., 1999; Nakagawa et al., 2005; Park et al., 2012). However, in a study using mice with chemically induced breast cancer, the invasion capacity of the tumor after seocalcitol  treatment is not affected (Liska et al., 2012). The effect of vitamin D analogs on angiogenesis has also been studied in vivo, but here the results are more conflicting. Some studies show no effect of vitamin D analogs on angiogenesis (Oades et al., 2002; Valrance et al., 2007), while others find decreased angiogenesis of xenograft tumors. Intraperitoneal injections of inecalcitol  decrease the vascularity of xenografted prostate cancer cells (Okamoto et al., 2012) and oral treatment of colorectal tumors in rats with alfacalcidol  also inhibits tumor angiogenesis (Iseki et al., 1999). All in vivo studies conclude that vitamin D analogs inhibit tumor growth but vitamin D and its analogs often do not influence tumor number. Seocalcitol  was given as chemoprevention in a transgenic mouse model for androgen-independent prostate cancer. Tumor growth is inhibited, however, there is no prevention in the development of tumors (Perez-Stable et al., 2002).
Table 3. In vivo studies in rodent cancer models treated with vitamin D analogs (intraperitoneal i.p.; subcutaneous s.c.) published between 2007 and 2013.
Since vitamin D and its analogs do not possess cytostatic properties, many in vivo studies have focused on vitamin D analog cancer treatment combined with radiotherapy and/or chemotherapy. When seocalcitol  is combined with radiotherapy in a xenograft model for breast cancer, the anti-cancer effects are more effective compared to monotherapy (Sundaram et al., 2003). Another analog, tacalcitol , has been investigated in colorectal cancer xenograft in combination with different standard chemotherapies. Different concentrations as well as administration routes of tacalcitol  or PRI-2205 (an analog of calcipotriol)  were used in combination with different concentrations of 5-fluorouracil (5-FU). Using specific analog doses and chemotherapy schedules, a synergistic effect on the prolongation of the life span of the mice is achieved (Milczarek et al., 2013a). Also the combination with irinotecan or oxaliplatin was investigated. In this study the mice also show a longer life span and a stronger tumor growth inhibition compared to monotherapy when certain doses of tacalcitol  and chemotherapy were used. However, some combinations were more toxic than the monotherapies (Milczarek et al., 2013b). Other studies report better effects when combining calcipotriol  and diclofenac in a non-melanoma skin cancer model (Pommergaard et al., 2013). However, the combination of vitamin D analogs with chemotherapy does not always result in additive or synergistic effects. Combining maxacalcitol  and 5-FU did not enhance anti-tumor effects in a chemically induced breast cancer model (Iino et al., 1992). Another study investigated calcipotriol  and its derivatives in breast and lung cancer in vivo models and concluded that these analogs and low dose cytostatics are not effective in the used models (Wietrzyk et al., 2007). Also tacalcitol  in combination with cyclophosphamide does not lead to a significant difference in tumor growth inhibition compared to the vehicle treatment (Wietrzyk et al., 2008).
In view of the promising results that certain vitamin D analogs show against cancer in vitro and in vivo animal models, some analogs have been tested in cancer patients (Table 4). Seocalcitol  is an analog that has been extensively studied in vitro and in vivo in different cancer models, however in clinical trials the results are rather disappointing. Patients with advanced breast or colon cancer were treated with different doses of seocalcitol  (most patients tolerate 7 μg/d) but none of them showed a complete or partial response (Gulliford et al., 1998). Also oral seocalcitol  treatment in patients with inoperable pancreatic cancer exhibited no objective anti-tumor activity (Evans et al., 2002). Two out of 33 patients with inoperable hepatocellular carcinoma showed a complete response after oral seocalcitol  treatment, however the majority of the patients presented stable or progressive disease (Dalhoff et al., 2003). Inecalcitol  is in an early stage II of its clinical trial in chronic lymphocytic leukemia. Fifteen patients received 2 mg/d orally and one patient had a 90% decrease in blood lymphocyte count after 10 months of treatment, in 8 other patients blood lymphocyte count stopped growing when the treatment started (Hybrigenics, 2014). Intravenous administration of paricalcitol , an analog that is approved for secondary hyperparathyroidism, also displayed no objective responses in patients with androgen-independent prostate cancer. However, elevated serum PTH levels, which are common for advanced prostate cancers, are reduced by the analog (Schwartz et al., 2005). Doxercalciferol , also used in the treatment against secondary hyperparathyroidism, was investigated in androgen-independent prostate cancer patients. A phase I study administered oral doxercalciferol  between 5 and 15 μg/d, which was well tolerated by the patients (Liu et al., 2002). In the following phase II study, patients were treated with 12.5 μg/d for a minimum of 8 weeks and 30% of these patients experienced stable disease for over 6 months (Liu et al., 2003). Oral treatment of non-Hodgkin's lymphoma patients with 1 μg/d alfacalcidol , a pre-metabolite of 1,25(OH)2D3, resulted in a low overall response. Out of 34 treated patients, only 4 had a complete response and 4 others showed a partial response to the treatment (Raina et al., 1991). Calcipotriol  is often used to treat skin psoriasis and has thus been investigated in patients with locally advanced or cutaneous metastases from breast cancer. In both studies the analog was applied topically at a dose of 100 μg/d. One study reported no response after 3 months of treatment (O'Brien et al., 1993), while in the other study 3 patients showed a 50% reduction in the diameter of treated lesions after 6 weeks (Bower et al., 1991). A more recently developed analog, ILX23-7553 , was investigated in 16 patients with advanced solid tumors but no objective response was seen (Jain et al., 2011). Similar to the in vivo studies, clinical trials have also combined vitamin D analogs with standard radiotherapy or chemotherapy. Metastatic breast cancer patients were given oral paricalcitol  doses between 2 and 7 μg/d in combination with taxane-based chemotherapy and this regimen was well tolerated by the patients (Lawrence et al., 2013). Oral inecalcitol  was given to patients with hormone-refractory prostate cancer in combination with docetaxel for maximum 18 weeks. This study had a response rate of 85% based on a PSA decline of at least 30% within 3 months of treatment (Hybrigenics, 2014). In a small study with acute non-lymphoid leukemia patients the combination of alfacalcidol  and chemotherapy resulted in 17% of the patients with a complete response and 45% with a partial response (Petrini et al., 1991). The same analog was combined with standard treatment of surgery, radiotherapy, and/or chemotherapy in glioblastoma and anaplastic astrocytomas. Here, 0.04 μg/kg/d alfacalcidol  was administered resulting in 27% of the patients with progressive regression of the lesion and complete clinical remission (Trouillas et al., 2001). In metastatic renal cell carcinoma patients, oral treatment of 1 μg alfacalcidol/d  was combined with a 3 weekly administration of interferon-α for minimal 3 months. In these patients 25% had a partial response to the combination therapy (Obara et al., 2008). Randomized, placebo-controlled studies have been conducted with oral doxercalciferol  or alfacalcidol . One study administered 10 μg/d doxercalciferol  or placebo during 4 weeks to patients with localized prostate cancer or high-grade prostatic intraepithelial neoplasia. However, no beneficial effects in serum or tissue markers were seen (Gee et al., 2013). Another study used the same dose in metastatic androgen-independent prostate cancer patients but combined the treatment with docetaxel. Also here, no enhanced PSA response rate or survival rate was seen after 4 weeks of treatment (Attia et al., 2008). Oral alfacalcidol  or placebo was given to patients with myelodysplastic syndromes. In the patients treated with the analog, a prolongation of leukemic transformation-free survival was seen compared to the placebo group (Motomura et al., 1991). Despite the promising in vitro and in vivo results of vitamin D analogs in cancer models, clinical trials have failed to proof the effects of vitamin D analogs in cancer patients. Vitamin D and its analogs lack cytotoxic activity, so using these analogs in combination with standard therapies such as radio- and chemotherapy is probably more effective than using the analogs as monotherapy. Next to the combination of analogs with standard cancer therapies, it is also possible that these analogs need to be given for a longer period of time or that treatment with analogs has to be started earlier, for example in early stages of disease or even as chemoprevention.
Conclusions and Perspectives
Vitamin D and its analogs exhibit strong antiproliferative and prodifferentiating effects on different normal and malignant cell types. Several vitamin D analogs have been approved for treating psoriasis, osteoporosis, and secondary hyperparathyroidism and are often used as first or second-line treatment option. Despite promising in vitro as well as in vivo results in various cancer models, vitamin D analog treatment in clinical trials with cancer patients failed to prove efficacy in most trials. Different combinations of analogs and standard cancer therapies should be further explored as well as the correct duration and timing of administration. To unravel the exact working mechanisms of vitamin D analogs more research studies should compare the effects of vitamin D analogs in different cell types to the mother compound. Furthermore, differences between 1,25(OH)2D3 and its analogs are probably more due to their differences in metabolism and coactivator recruitment than from different genetic regulations. However, some fields such as epigenetics and proteomics remain largely unexplored in comparing the potentially distinctive effects of 1,25(OH)2D3 and its analogs. Since all current genomic and transcriptomic studies focus on established human cell lines, micro-array, and ChIP techniques comparing the effects of 1,25(OH)2D3 and its analogs on human primary tumor tissues should be investigated in the future.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
This work was supported by grants from the Fund for Scientific Research (G.0587.09; G.0A17.14N) and the KU Leuven (GOA/14/010).
Abe, J., Nakano, T., Nishii, Y., Matsumoto, T., Ogata, E., and Ikeda, K. (1991). A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129, 832–837. doi: 10.1210/endo-129-2-832
Akhter, J., Chen, X., Bowrey, P., Bolton, E. J., and Morris, D. L. (1997). Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis. Colon Rectum 40, 317–321. doi: 10.1007/BF02050422
Albert, D. M., Kumar, A., Strugnell, S. A., Darjatmoko, S. R., Lokken, J. M., Lindstrom, M. J., et al. (2004a). Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model. Arch. Ophthalmol. 122, 1365–1369. doi: 10.1001/archopht.122.9.1365
Albert, D. M., Kumar, A., Strugnell, S. A., Darjatmoko, S. R., Lokken, J. M., Lindstrom, M. J., et al. (2004b). Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models. Arch. Ophthalmol. 122, 1357–1362. doi: 10.1001/archopht.122.9.1357
Attia, S., Eickhoff, J., Wilding, G., McNeel, D., Blank, J., Ahuja, H., et al. (2008). Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin. Cancer Res. 14, 2437–2443. doi: 10.1158/1078-0432.CCR-07-4274
Bae, S., Yalamarti, B., Ke, Q., Choudhury, S., Yu, H., Karumanchi, S. A., et al. (2011). Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. Cardiovasc. Res. 91, 632–639. doi: 10.1093/cvr/cvr133
Baeke, F., Korf, H., Overbergh, L., Verstuyf, A., Thorrez, L., Van Lommel, L., et al. (2011). The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J. Immunol. 186, 132–142. doi: 10.4049/jimmunol.1000695
Berkovich, L., Sintov, A. C., and Ben-Shabat, S. (2013). Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D3 analogs, in-vitro and in-vivo studies. Invest. New Drugs 31, 247–255. doi: 10.1007/s10637-012-9839-1
Bhatia, V., Saini, M. K., Shen, X., Bi, L. X., Qiu, S., Weigel, N. L., et al. (2009). EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol. Cancer Ther. 8, 1787–1798. doi: 10.1158/1535-7163.MCT-09-0064
Bower, M., Colston, K. W., Stein, R. C., Hedley, A., Gazet, J. C., Ford, H. T., et al. (1991). Topical calcipotriol treatment in advanced breast cancer. Lancet 337, 701–702. doi: 10.1016/0140-6736(91)90280-3
Chiang, K. C., Yeh, C. N., Hsu, J. T., Yeh, T. S., Jan, Y. Y., Wu, C. T., et al. (2013). Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo. Cell Cycle 12, 1316–1325. doi: 10.4161/cc.24445
Coburn, J. W., Maung, H. M., Elangovan, L., Germain, M. J., Lindberg, J. S., Sprague, S. M., et al. (2004). Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am. J. Kidney Dis. 43, 877–890. doi: 10.1053/j.ajkd.2004.01.012
Colston, K., Colston, M. J., and Feldman, D. (1981). 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108, 1083–1086. doi: 10.1210/endo-108-3-1083
Coyne, D., Acharya, M., Qiu, P., Abboud, H., Batlle, D., Rosansky, S., et al. (2006). Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 47, 263–276. doi: 10.1053/j.ajkd.2005.10.007
Dalhoff, K., Dancey, J., Astrup, L., Skovsgaard, T., Hamberg, K. J., Lofts, F. J., et al. (2003). A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 89, 252–257. doi: 10.1038/sj.bjc.6601104
Danielsson, C., Nayeri, S., Wiesinger, H., Thieroff-Ekerdt, R., and Carlberg, C. (1996). Potent gene regulatory and antiproliferative activities of 20-methyl analogues of 1,25 dihydroxyvitamin D3. J. Cell. Biochem. 63, 199–206. doi: 10.1002/(SICI)1097-4644(19961101)63:2<199::AID-JCB7>3.0.CO;2-T
Dilworth, F. J., Williams, G. R., Kissmeyer, A. M., Nielsen, J. L., Binderup, E., Calverley, M. J., et al. (1997). The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology 138, 5485–5496. doi: 10.1210/en.138.12.5485
Ding, N., Yu, R. T., Subramaniam, N., Sherman, M. H., Wilson, C., Rao, R., et al. (2013). A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153, 601–613. doi: 10.1016/j.cell.2013.03.028
Eelen, G., Gysemans, C., Verlinden, L., Vanoirbeek, E., De Clercq, P., Van Haver, D., et al. (2007). Mechanism and potential of the growth-inhibitory actions of vitamin D and ana-logs. Curr. Med. Chem. 14, 1893–1910. doi: 10.2174/092986707781058823
Eelen, G., Valle, N., Sato, Y., Rochel, N., Verlinden, L., De Clercq, P., et al. (2008). Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor. Chem. Biol. 15, 1029–1034. doi: 10.1016/j.chembiol.2008.08.008
Eelen, G., Verlinden, L., Rochel, N., Claessens, F., De Clercq, P., Vandewalle, M., et al. (2005). Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol. Pharmacol. 67, 1566–1573. doi: 10.1124/mol.104.008730
El Abdaimi, K., Dion, N., Papavasiliou, V., Cardinal, P. E., Binderup, L., Goltzman, D., et al. (2000). The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res. 60, 4412–4418.
Evans, T. R., Colston, K. W., Lofts, F. J., Cunningham, D., Anthoney, D. A., Gogas, H., et al. (2002). A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer 86, 680–685. doi: 10.1038/sj.bjc.6600162
Fichera, A., Little, N., Dougherty, U., Mustafi, R., Cerda, S., Li, Y. C., et al. (2007). A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J. Surg. Res. 142, 239–245. doi: 10.1016/j.jss.2007.02.038
Flanagan, L., Packman, K., Juba, B., O'Neill, S., Tenniswood, M., and Welsh, J. (2003). Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J. Steroid Biochem. Mol. Biol. 84, 181–192. doi: 10.1016/S0960-0760(03)00028-1
Gee, J., Bailey, H., Kim, K., Kolesar, J., Havighurst, T., Tutsch, K. D., et al. (2013). Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1alpha-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate 73, 970–978. doi: 10.1002/pros.22644
Gonzalez-Pardo, V., Martin, D., Gutkind, J. S., Verstuyf, A., Bouillon, R., de Boland, A. R., et al. (2010). 1 Alpha,25-dihydroxyvitamin D3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor in vitro and in vivo. Endocrinology 151, 23–31. doi: 10.1210/en.2009-0650
Griffin, M. D., Xing, N., and Kumar, R. (2004). Gene expression profiles in dendritic cells conditioned by 1alpha,25-dihydroxyvitamin D3 analog. J. Steroid Biochem. Mol. Biol. 89–90, 443–448. doi: 10.1016/j.jsbmb.2004.03.039
Grostern, R. J., Bryar, P. J., Zimbric, M. L., Darjatmoko, S. R., Lissauer, B. J., Lindstrom, M. J., et al. (2002). Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model. Arch. Ophthalmol. 120, 607–612. doi: 10.1001/archopht.120.5.607
Gulliford, T., English, J., Colston, K. W., Menday, P., Moller, S., and Coombes, R. C. (1998). A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br. J. Cancer 78, 6–13. doi: 10.1038/bjc.1998.434
Hagino, H., Takano, T., Fukunaga, M., Shiraki, M., Nakamura, T., and Matsumoto, T. (2013). Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis. J. Bone Miner. Metab. 31, 183–189. doi: 10.1007/s00774-012-0397-6
Hamdy, N. A., Kanis, J. A., Beneton, M. N., Brown, C. B., Juttmann, J. R., Jordans, J. G., et al. (1995). Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310, 358–363. doi: 10.1136/bmj.310.6976.358
Hansen, C. M., and Maenpaa, P. H. (1997). EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem. Pharmacol. 54, 1173–1179. doi: 10.1016/S0006-2952(97)00181-0
Hara, K., Kusuzaki, K., Takeshita, H., Kuzuhara, A., Tsuji, Y., Ashihara, T., et al. (2001). Oral administration of 1 alpha hydroxyvitamin D3 inhibits tumor growth and metastasis of a murine osteosarcoma model. Anticancer Res. 21, 321–324.
Harada, S., Mizoguchi, T., Kobayashi, Y., Nakamichi, Y., Takeda, S., Sakai, S., et al. (2012). Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J. Bone Miner. Res. 27, 461–473. doi: 10.1002/jbmr.555
Hybrigenics. (2014). Inecalcitol. [Internet] Paris, France: Hybrigenics [cited 2014 29/01]. Available online at: http://www.hybrigenics.com/contents/pharma-1/inecalcitol-1
Iino, Y., Yoshida, M., Sugamata, N., Maemura, M., Ohwada, S., Yokoe, T., et al. (1992). 1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Breast Cancer Res. Treat. 22, 133–140. doi: 10.1007/BF01833343
Iseki, K., Tatsuta, M., Uehara, H., Iishi, H., Yano, H., Sakai, N., et al. (1999). Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int. J. Cancer 81, 730–733. doi: 10.1002/(SICI)1097-0215(19990531)81:5<730::AID-IJC11>3.0.CO;2-Q
Ito, M., Nakamura, T., Fukunaga, M., Shiraki, M., and Matsumoto, T. (2011). Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone 49, 328–334. doi: 10.1016/j.bone.2011.05.002
Jain, R. K., Trump, D. L., Egorin, M. J., Fernandez, M., Johnson, C. S., and Ramanathan, R. K. (2011). A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors. Invest. New Drugs 29, 1420–1425. doi: 10.1007/s10637-010-9492-5
James, S. Y., Mercer, E., Brady, M., Binderup, L., and Colston, K. W. (1998). EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br. J. Pharmacol. 125, 953–962. doi: 10.1038/sj.bjp.0702103
Jensen, S. S., Madsen, M. W., Lukas, J., Binderup, L., and Bartek, J. (2001). Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol. Endocrinol. 15, 1370–1380. doi: 10.1210/mend.15.8.0673
Kawa, S., Yoshizawa, K., Nikaido, T., and Kiyosawa, K. (2005). Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. J. Steroid Biochem. Mol. Biol. 97, 173–177. doi: 10.1016/j.jsbmb.2005.06.021
Kawa, S., Yoshizawa, K., Tokoo, M., Imai, H., Oguchi, H., Kiyosawa, K., et al. (1996). Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 110, 1605–1613. doi: 10.1053/gast.1996.v110.pm8613068
Kissmeyer, A. M., Binderup, E., Binderup, L., Mork Hansen, C., Andersen, N. R., Makin, H. L., et al. (1997). Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem. Pharmacol. 53, 1087–1097. doi: 10.1016/S0006-2952(96)00816-7
Kriebitzsch, C., Verlinden, L., Eelen, G., Tan, B. K., Van Camp, M., Bouillon, R., et al. (2009). The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells–a microarray approach. Anticancer Res. 29, 3471–3483.
Lambert, J. R., Eddy, V. J., Young, C. D., Persons, K. S., Sarkar, S., Kelly, J. A., et al. (2010). A vitamin D receptor-alkylating derivative of 1alpha,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev. Res. (Phila.) 3, 1596–1607. doi: 10.1158/1940-6207.CAPR-10-0122
Lawrence, J. A., Akman, S. A., Melin, S. A., Case, L. D., and Schwartz, G. G. (2013). Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Cancer Biol. Ther. 14, 476–480. doi: 10.4161/cbt.24350
Lee, H. J., Paul, S., Atalla, N., Thomas, P. E., Lin, X., Yang, I., et al. (2008). Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev. Res. (Phila.) 1, 476–484. doi: 10.1158/1940-6207.CAPR-08-0084
Lee, H. J., So, J. Y., DeCastro, A., Smolarek, A., Paul, S., Maehr, H., et al. (2010). Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J. Steroid Biochem. Mol. Biol. 121, 408–412. doi: 10.1016/j.jsbmb.2010.03.053
Lin, R., Nagai, Y., Sladek, R., Bastien, Y., Ho, J., Petrecca, K., et al. (2002). Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 16, 1243–1256. doi: 10.1210/mend.16.6.0874
Liska, J., Macejova, D., Ondkova, S., and Brtko, J. (2012). Morphology of 1-methyl-1-nitrosourea induced rat mammary tumours after treatment with precursor of phytanic acid or its combination with vitamin D analogue. Endocr. Regul. 46, 21–26. doi: 10.4149/endo_2012_021
Liu, G., Oettel, K., Ripple, G., Staab, M. J., Horvath, D., Alberti, D., et al. (2002). Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin. Cancer Res. 8, 2820–2827.
Liu, G., Wilding, G., Staab, M. J., Horvath, D., Miller, K., Dresen, A., et al. (2003). Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin. Cancer Res. 9, 4077–4083.
Liu, Y. Y., Nguyen, C., Ali Gardezi, S. A., Schnirer, I., and Peleg, S. (2001). Differential regulation of heterodimerization by 1alpha,25-dihydroxyvitamin D(3) and its 20-epi analog. Steroids 66, 203–212. doi: 10.1016/S0039-128X(00)00151-3
Liu, Y. Y., Nguyen, C., and Peleg, S. (2000). Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor. Mol. Endocrinol. 14, 1776–1787. doi: 10.1210/mend.14.11.0560
Lokeshwar, B. L., Schwartz, G. G., Selzer, M. G., Burnstein, K. L., Zhuang, S. H., Block, N. L., et al. (1999). Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol. Biomarkers Prev. 8, 241–248.
Lundqvist, J., Hansen, S. K., and Lykkesfeldt, A. E. (2013). Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase. Biochim. Biophys. Acta 1833, 40–47. doi: 10.1016/j.bbamcr.2012.10.012
Ma, Y., Yu, W. D., Hidalgo, A. A., Luo, W., Delansorne, R., Johnson, C. S., et al. (2013). Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle 12, 743–752. doi: 10.4161/cc.23846
Macejova, D., Ondkova, S., Jakubikova, L., Mlynarcikova, A., Scsukova, S., Liska, J., et al. (2011). MNU-induced mammary gland carcinogenesis: chemopreventive and therapeutic effects of vitamin D and Seocalcitol on selected regulatory vitamin D receptor pathways. Toxicol. Lett. 207, 60–72. doi: 10.1016/j.toxlet.2011.07.029
Matsumoto, T., Ito, M., Hayashi, Y., Hirota, T., Tanigawara, Y., Sone, T., et al. (2011). A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures–a randomized, active comparator, double-blind study. Bone 49, 605–612. doi: 10.1016/j.bone.2011.07.011
Milczarek, M., Psurski, M., Kutner, A., and Wietrzyk, J. (2013a). Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer 13:294. doi: 10.1186/1471-2407-13-294
Milczarek, M., Rosinska, S., Psurski, M., Maciejewska, M., Kutner, A., and Wietrzyk, J. (2013b). Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res. 33, 433–444.
Motomura, S., Kanamori, H., Maruta, A., Kodama, F., and Ohkubo, T. (1991). The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am. J. Hematol. 38, 67–68. doi: 10.1002/ajh.2830380112
Nakagawa, K., Sasaki, Y., Kato, S., Kubodera, N., and Okano, T. (2005). 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26, 1044–1054. doi: 10.1093/carcin/bgi049
Oades, G. M., Dredge, K., Kirby, R. S., and Colston, K. W. (2002). Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int. 90, 607–616. doi: 10.1046/j.1464-410X.2002.02964.x
Obara, W., Mizutani, Y., Oyama, C., Akaza, H., Ishii, N., Kohri, K., et al. (2008). Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma. Int. J. Urol. 15, 794–799. doi: 10.1111/j.1442-2042.2008.02086.x
Okamoto, R., Delansorne, R., Wakimoto, N., Doan, N. B., Akagi, T., Shen, M., et al. (2012). Inecalcitol, an analog of 1alpha,25(OH)(2) D(3), induces growth arrest of androgen-dependent prostate cancer cells. Int. J. Cancer 130, 2464–2473. doi: 10.1002/ijc.26279
Okamoto, R., Gery, S., Kuwayama, Y., Borregaard, N., Ho, Q., Alvarez, R., et al. (2014). Novel Gemini vitamin D3 analogs: large structure/function analysis and ability to induce antimicrobial peptide. Int. J. Cancer 134, 207–217. doi: 10.1002/ijc.28328
Okano, T., Tsugawa, N., Masuda, S., Takeuchi, A., Kobayashi, T., and Nishii, Y. (1989a). Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1 alpha,25-dihydroxyvitamin D3. J. Nutr. Sci. Vitaminol. (Tokyo) 35, 529–533. doi: 10.3177/jnsv.35.529
Okano, T., Tsugawa, N., Masuda, S., Takeuchi, A., Kobayashi, T., Takita, Y., et al. (1989b). Regulatory activities of 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem. Biophys. Res. Commun. 163, 1444–1449. doi: 10.1016/0006-291X(89)91140-6
Park, M. R., Lee, J. H., Park, M. S., Hwang, J. E., Shim, H. J., Cho, S. H., et al. (2012). Suppressive effect of 19-nor-1alpha-25-dihydroxyvitamin D2 on gastric cancer cells and peritoneal metastasis model. J. Korean Med. Sci. 27, 1037–1043. doi: 10.3346/jkms.2012.27.9.1037
Perez-Stable, C. M., Schwartz, G. G., Farinas, A., Finegold, M., Binderup, L., Howard, G. A., et al. (2002). The G gamma / T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Cancer Epidemiol. Biomarkers Prev. 11, 555–563.
Petrini, M., Caracciolo, F., Corini, M., Valentini, P., Sabbatini, A. R., and Grassi, B. (1991). Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia: pilot study. Haematologica 76, 200–203.
Pommergaard, H. C., Burcharth, J., Rosenberg, J., and Raskov, H. (2013). Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. Anticancer Res. 33, 3033–3039.
Prudencio, J., Akutsu, N., Benlimame, N., Wang, T., Bastien, Y., Lin, R., et al. (2001). Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 93, 745–753. doi: 10.1093/jnci/93.10.745
Quack, M., and Carlberg, C. (1999). Selective recognition of vitamin D receptor conformations mediates promoter selectivity of vitamin D analogs. Mol. Pharmacol. 55, 1077–1087. doi: 10.1124/mol.55.6.1077
Raina, V., Cunningham, D., Gilchrist, N., and Soukop, M. (1991). Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br. J. Cancer 63, 463–465. doi: 10.1038/bjc.1991.108
Schwartz, G. G., Eads, D., Naczki, C., Northrup, S., Chen, T., and Koumenis, C. (2008). 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther. 7, 430–436. doi: 10.4161/cbt.7.3.5418
Schwartz, G. G., Hall, M. C., Stindt, D., Patton, S., Lovato, J., and Torti, F. M. (2005). Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin. Cancer Res. 11(24 Pt 1), 8680–8685. doi: 10.1158/1078-0432.CCR-05-1237
Schwinn, M. K., and DeLuca, H. F. (2007). Differential recruitment of coactivators to the vitamin D receptor transcriptional complex by 1alpha,25-dihydroxyvitamin D3 analogs. Arch. Biochem. Biophys. 465, 443–451. doi: 10.1016/j.abb.2007.06.015
Seubwai, W., Wongkham, C., Puapairoj, A., Okada, S., and Wongkham, S. (2010). 22-oxa-1,25-dihydroxyvitamin D3 efficiently inhibits tumor growth in inoculated mice and primary histoculture of cholangiocarcinoma. Cancer 116, 5535–5543. doi: 10.1002/cncr.25478
Shalhoub, V., Shatzen, E. M., Ward, S. C., Young, J. I., Boedigheimer, M., Twehues, L., et al. (2010). Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol. J. Cell. Biochem. 111, 911–921. doi: 10.1002/jcb.22779
Shankar, V. N., Dilworth, F. J., Makin, H. L., Schroeder, N. J., Trafford, D. J., Kissmeyer, A. M., et al. (1997). Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain. Biochem. Pharmacol. 53, 783–793. doi: 10.1016/S0006-2952(96)00815-5
Shinaberger, C. S., Kopple, J. D., Kovesdy, C. P., McAllister, C. J., van Wyck, D., Greenland, S., et al. (2008). Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 1769–1776. doi: 10.2215/CJN.01760408
So, J. Y., Lee, H. J., Smolarek, A. K., Paul, S., Wang, C. X., Maehr, H., et al. (2011). A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol. Pharmacol. 79, 360–367. doi: 10.1124/mol.110.068403
Sundaram, S., Sea, A., Feldman, S., Strawbridge, R., Hoopes, P. J., Demidenko, E., et al. (2003). The combination of a potent vitamin D3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin. Cancer Res. 9, 2350–2356.
Teng, M., Wolf, M., Lowrie, E., Ofsthun, N., Lazarus, J. M., and Thadhani, R. (2003). Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 349, 446–456. doi: 10.1056/NEJMoa022536
Tentori, F., Hunt, W. C., Stidley, C. A., Rohrscheib, M. R., Bedrick, E. J., Meyer, K. B., et al. (2006). Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 70, 1858–1865. doi: 10.1038/sj.ki.5001868
Trouillas, P., Honnorat, J., Bret, P., Jouvet, A., and Gerard, J. P. (2001). Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. J. Neurooncol. 51, 57–66. doi: 10.1023/A:1006437003352
Uchiyama, Y., Higuchi, Y., Takeda, S., Masaki, T., Shira-Ishi, A., Sato, K., et al. (2002). ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30, 582–588. doi: 10.1016/S8756-3282(02)00682-8
Valrance, M. E., Brunet, A. H., and Welsh, J. (2007). Vitamin D receptor-dependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo. Endocrinology 148, 4887–4894. doi: 10.1210/en.2007-0267
van den Bemd, G. C., Pols, H. A., Birkenhager, J. C., and van Leeuwen, J. P. (1996). Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060. Proc. Natl. Acad. Sci. U.S.A. 93, 10685–10690. doi: 10.1073/pnas.93.20.10685
van Ginkel, P. R., Yang, W., Marcet, M. M., Chow, C. C., Kulkarni, A. D., Darjatmoko, S., et al. (2007). 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma. J. Neurooncol. 85, 255–262. doi: 10.1007/s11060-007-9418-z
Vanoirbeek, E., Eelen, G., Verlinden, L., Marchal, K., Engelen, K., De Moor, B., et al. (2009). Microarray analysis of MCF-7 breast cancer cells treated with 1,25-dihydroxyvitamin D3 or a 17-methyl-D-ring analog. Anticancer Res. 29, 3585–3590.
VanWeelden, K., Flanagan, L., Binderup, L., Tenniswood, M., and Welsh, J. (1998). Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 139, 2102–2110. doi: 10.1210/en.139.4.2102
Vegesna, V., O'Kelly, J., Said, J., Uskokovic, M., Binderup, L., and Koeffle, H. P. (2003). Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res. 23, 283–289.
Wietrzyk, J., Nevozhay, D., Filip, B., Milczarek, M., and Kutner, A. (2007). The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res. 27, 3387–3398.
Wietrzyk, J., Nevozhay, D., Milczarek, M., Filip, B., and Kutner, A. (2008). Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother. Pharmacol. 62, 787–797. doi: 10.1007/s00280-007-0666-6
Wietrzyk, J., Pelczynska, M., Madej, J., Dzimira, S., Kusnierczyk, H., Kutner, A., et al. (2004). Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191). Steroids 69, 629–635. doi: 10.1016/j.steroids.2004.05.015
Wu-Wong, J. R., Nakane, M., Ma, J., Ruan, X., and Kroeger, P. E. (2007). VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J. Cell. Biochem. 100, 1395–1405. doi: 10.1002/jcb.21133
Yamamoto, H., Shevde, N. K., Warrier, A., Plum, L. A., DeLuca, H. F., and Pike, J. W. (2003). 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J. Biol. Chem. 278, 31756–31765. doi: 10.1074/jbc.M304737200
Yoon, J. S., Kim, J. Y., Park, H. K., Kim, E. S., Ahn, K. S., Yoon, S. S., et al. (2008). Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia. Int. J. Oncol. 32, 387–396. doi: 10.3892/ijo.32.2.387
Zella, L. A., Meyer, M. B., Nerenz, R. D., and Pike, J. W. (2009). The enhanced hypercalcemic response to 20-epi-1,25-dihydroxyvitamin D3 results from a selective and prolonged induction of intestinal calcium-regulating genes. Endocrinology 150, 3448–3456. doi: 10.1210/en.2009-0113
Keywords: vitamin D, analogs, pleiotropic effects, cancer
Citation: Leyssens C, Verlinden L and Verstuyf A (2014) The future of vitamin D analogs. Front. Physiol. 5:122. doi: 10.3389/fphys.2014.00122
Received: 06 February 2014; Paper pending published: 19 February 2014;
Accepted: 13 March 2014; Published online: 03 April 2014.
Edited by:Carsten Carlberg, University of Eastern Finland, Finland
Reviewed by:Ferdinand Molnár, University of Eastern Finland, Finland
Antonio Mourino, Universidad de Santiago, Spain
Copyright © 2014 Leyssens, Verlinden and Verstuyf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Annemieke Verstuyf, Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Herestraat 49, bus 902, 3000 Leuven, Belgium e-mail: email@example.com